1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. News
  7. Summary
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-07-04 am EDT
13.90 EUR   -1.84%
07/01Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the Registration of Maxigesic IV®
GL
07/01Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the Registration of Maxigesic IV®
AQ
07/01Hyloris Pharmaceuticals Receives US FDA Request For Additional Information On Maxigesic
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in Interstitial Cystitis

12/17/2021 | 01:00am EDT

HylorisPharmaceuticals SA announced that it has entered into a strategic collaboration with Vaneltix Pharma Inc. for the development and commercialisation of AlenuraTM as first-line drug treatment for acute pain in interstitial cystitis /bladder pain syndrome (IC/BPS). AlenuraTM is a patented, innovative, clinical-stage bladder instillation product candidate that combines lidocaine, a well-established anaesthetic, in a new alkalinized form with heparin, a component of mucous membranes2. The novel dual mode-of-action, AlenuraTM has the unique potential to i) immediately relieve pain, and ii) augment the mucous layer of the bladder. In previous clinical studies, AlenuraTM was well-tolerated and demonstrated to be more effective in terms of pain relief, urgency response and improvement of symptoms compared to placebo, and lidocaine alone3.


© S&P Capital IQ 2021
All news about HYLORIS PHARMACEUTICALS SA
07/01Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the R..
GL
07/01Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the R..
AQ
07/01Hyloris Pharmaceuticals Receives US FDA Request For Additional Information On Maxigesic
MT
07/01US FDA seeks more information on Maxigesic IV® application
GL
07/01Hyloris Pharmaceuticals SA Receives Complete Response Letter from the US Food and Drug ..
CI
07/01HYLORIS PHARMACEUTICALS : Maxigesic - Update
PU
06/26Certain Shares of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agreement Ending ..
CI
06/22HYLORIS PHARMACEUTICALS SA : Monthly statement on outstanding equity shares and voting rig..
CO
04/30HYLORIS PHARMACEUTICALS SA : Annual Report
CO
04/05HYLORIS PHARMACEUTICALS SA : Crossing thresholds
CO
More news
Financials
Sales 2022 10,0 M 10,4 M 10,4 M
Net income 2022 -11,0 M -11,5 M -11,5 M
Net cash 2022 27,0 M 28,2 M 28,2 M
P/E ratio 2022 -33,9x
Yield 2022 -
Capitalization 373 M 388 M 388 M
EV / Sales 2022 34,6x
EV / Sales 2023 24,5x
Nbr of Employees 21
Free-Float 47,2%
Chart HYLORIS PHARMACEUTICALS SA
Duration : Period :
Hyloris Pharmaceuticals SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HYLORIS PHARMACEUTICALS SA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 13,90 €
Average target price 20,25 €
Spread / Average Target 45,7%
EPS Revisions
Managers and Directors
Stijn van Rompay Chief Executive Officer & Executive Director
Jean-Luc Vandebroek Chief Financial Officer
Stefan Yee Chairman
Dietmar Aichhorn Chief Operating Officer
Marc Foidart Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HYLORIS PHARMACEUTICALS SA-18.15%395
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782